Fig. 1.
Overview of the final population pharmacokinetic model for remdesivir (RDV) and its metabolites: GS‐704277 and GS‐441524 that was developed using non-linear mixed effect modeling software. The model described each moiety to have a 2-compartment distribution, with sequential metabolism occurring from the central compartment, in addition to remdesivir peripheral metabolism to GS‐774277. And elimination is modeled to occur in the central compartments. CL total body clearance (CL), Vdc and Vdp the volume of distribution for central and peripheral compartments, Q inter-compartmental clearance, CLm formation clearance of metabolites